Pharma channel feed

No­vo nabs over a third of di­a­betes mar­ket, a year ahead of sched­ule

Last year

Mod­er­na sticks to long-term strat­e­gy in first-quar­ter up­date, ends pact with Metageno­mi

Last year

FDA asks for more da­ta on Dupix­ent in COPD in move that could de­lay a de­ci­sion

Last year
R&D
FDA+

No­var­tis makes a $1B ra­dio­phar­ma deal, buy­ing Mar­i­ana On­col­o­gy

Last year
Startups
Deals

No­vo’s GLP-1 sales boost prof­its, yet full po­ten­tial still curbed by sup­ply squeeze

Last year

J&J fol­lows Bris­tol My­ers in ap­peal of judge's rul­ing against com­pa­nies in IRA law­suit

Last year
Law

Pfiz­er sticks to the script in first-quar­ter up­date as cost cuts are 'large­ly com­plete'

Last year

Boehringer puts a tar­get on Hu­mi­ra, says push­ing it off for­mu­la­ries is nec­es­sary

Last year

J&J pro­pos­es $6.5B talc set­tle­ment plan

Last year
Law

Sen­a­tor al­leges GSK is shirk­ing its com­mit­ment to low­er in­haler costs

Last year
FDA+

GSK ex­pe­dites Blenrep time­lines as it eyes sec­ond chance in mul­ti­ple myelo­ma

Last year

GSK still rid­ing vac­cine sales wave, push­ing 2024 fore­casts high­er

Last year

Pfiz­er makes small pipeline changes in first-quar­ter up­date

Last year

Neu­ro­crine wins ap­proval of In­grez­za 'sprin­kle' for­mu­la­tion for pa­tients with trou­ble swal­low­ing

Last year
FDA+

FTC tar­gets more drug patents, go­ing af­ter obe­si­ty, di­a­betes and asth­ma med­ica­tions

Last year
FDA+

FDA asks for pub­lic in­put on ad­vi­so­ry com­mit­tee re­forms

Last year
FDA+

Mar­ket­ingRx roundup: Mod­er­na de­buts so­cial me­dia sci­ence se­ries; Boehringer ex­pands NY men­tal health ex­hib­it

Last year
Marketing

Lil­ly scraps tri­als of Verzenio, Jar­diance and a gene ther­a­py from Pre­vail

Last year
R&D

Re­al Chem­istry de­buts a one-stop dash­board for all things GLP-1

Last year
Marketing

Up­dat­ed: Lil­ly boosts sales guid­ance by $2B, but GLP-1 sup­ply con­straints still a fo­cus

Last year
Manufacturing

Fed­er­al judge throws out two drug­mak­er IRA law­suits in win for gov­ern­ment

Last year
Law

FDA con­verts Pfiz­er's Tiv­dak to full ap­proval in cer­vi­cal can­cer

Last year
FDA+

FDA fi­nal­izes long-await­ed rule to bring lab tests un­der its purview

Last year
FDA+
Diagnostics

No­vo Nordisk's once-week­ly in­sulin will face FDA ad­comm in May, fol­low­ing re­view ex­ten­sion

Last year
FDA+
First page Previous page 55565758596061 Next page Last page
A service from the Financial Times